GILD - CIK 0000882095
GILEAD SCIENCES, INC. trades as GILD and has a market capitalization of $151.05 B, making it the #99 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $29.44B, up 2.4% from the prior year and net income of $8.51B. This page tracks GILEAD SCIENCES, INC. through 981 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years GILEAD SCIENCES, INC.'s revenue declined from $30.39B to $29.44B, a compound annual decline rate of 0.4%. Net profit margin compressed from 44.4% to 28.9% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-20 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Prospectus supplement | 424B5 | 2026-05-18 |
| Insider sale notice | 144 | 2026-05-15 |
| Insider sale notice | 144 | 2026-05-15 |
| Free writing prospectus | FWP | 2026-05-14 |
| Prospectus supplement | 424B5 | 2026-05-14 |
**_–_ _Chronic HDV is considered the most severe form of viral hepatitis due to rapid disease progression towards liver failure and liver-related death_ _–_**
**_– Recommendation Based on ASCENT-03 Study, Demonstrating Highly Statistically Significant and Clinically Meaningful Progression-Free Survival Versus Chemotherapy in PD-(L)1 Inhibitor Ineligible Patients–_**
**_\- The disease remains a public health challenge with an estimated 50,000 to 90,000 new cases each year -_**
– **_Acquisition Builds on Gilead’s Leadership in Oncology with Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform_**–
The largest companies sharing GILEAD SCIENCES, INC.'s SEC industry classification (biological products, (no diagnostic substances)).
GILEAD SCIENCES, INC. (GILD) has a market capitalization of $151.05 B as of 2026-06-10, ranking #99 among US-listed companies.
GILEAD SCIENCES, INC. reported revenue of $29.44B for fiscal year 2025, an increase of 2.4% year over year.
Yes. GILEAD SCIENCES, INC. reported net income of $8.51B in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
**_– ASCO Presentations on Trodelvy® in First-line Metastatic Triple-Negative Breast Cancer and Anito-cel in Relapsed or Refractory Multiple Myeloma Build Toward Potential Commercial Launches –_**